Research and Markets (http://www.researchandmarkets.com/research/p5lmvs/burnsglobal_api) has announced the addition of the "Burns-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016" report to their offering.
The Report, Burns-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.
Key Topics Covered:
- A snapshot of the global Market and Phase III therapeutics scenario for Burns.
- A review of the marketed products under prescription for Burns, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Burns with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
Benefits of this Report:
- Evaluate the marketing status and exclusivity details of Burns key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Burns.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Burns.
- API intelligence over marketed drugs for Burns and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and design strategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
Report Structure:
1. Indication Overview
2. Market Drugs Landscape
3. Global API Manufacturers Assessment
4. Phase III Drugs Landscape
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Burns
7. Phase III Drugs for Burns
8. Discontinued Drugs for Burns
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer
For more information visit http://www.researchandmarkets.com/research/p5lmvs/burnsglobal_api
View source version on businesswire.com: http://www.businesswire.com/news/home/20160113006071/en/